Michael D. Loberg

Michael D. Loberg (board member) discloses dealings in 3 companies, chiefly Arqule Inc, IGM Biosciences, Inc. and AMAG Pharmaceuticals Inc. Between 5 June 2006 and 29 September 2023, the trades on record add up to 283 filings.

Both buying and selling appear: 50 purchases worth €1.1M, against 10 sales worth €1.2M. Sales outweigh purchases by €121k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 181 share grants and 11 option exercises.

A typical purchase (the median) is worth €788. On 2 out of 5 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

Most recently, on 3 October 2023, the filings show a share grant in IGM Biosciences, Inc. The most recent open-market purchase was published on 3 October 2022, 1,497 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.